A gRNA TARGETING HPK1 AND A METHOD FOR EDITING HPK1 GENE
AssigneeBeijing Yufan Biotechnologies Co., Ltd.
InventorsXuebin LIAO, Jingwen SI
Life of this patent
Estimating the term…
Abstract
Provided is a gRNA targeting HPK1 and a method for editing HPK1 gene. The method can knock out the T cell HPK1 gene, enhance the T cell killing activity, increase the Th1 cytokine level of peripheral blood mononuclear cells, and knock out of the T cell HPK1 gene can also down-regulate the expression of PD-1 and TIM3 on the T cell surface and can inhibit the T cell depletion.
Claims32
An immune cell comprising a genetic disruption of a HPK-1 gene, and/or an agent that induces or is capable of inducing a genetic disruption of the HPK-1 gene.
(canceled)
5-17. (canceled)
19-27. (canceled)
(canceled)
31-50. (canceled)
A method of producing a genetically engineered immune cell, altering a T cell, or enhancing cytotoxicity, inhibiting exhaustion, and/or enhancing infiltration in spleen and/or tumors of an immune cell population, comprising (a) contacting the immune cell, T cell or immune cell population with an agent that induces or is capable of inducing a genetic disruption of a HPK1 gene.
52-53. (canceled)
55-58. (canceled)
60-63. (canceled)
65-83. (canceled)
85-88. (canceled)
A CAR-T cell population characterized in that:
- a. at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% of cells in the cell population do not express the endogenous HPK-1 polypeptide;
- do not contain a contiguous HPK-1 gene, a HPK-1 gene, and/or a functional HPK-1 gene;
- or a HPK-1 gene knockout efficiency in the cell population of at least about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%;
- and
- b. at least about 50%, 75%, 80%, 85%, or 90% of the cells express a chimeric antigen receptor on cell surface.
91-92. (canceled)
94-97. (canceled)
Dependencies are inferred from the claim text.